血清CA9在前列腺癌预后评估中的作用
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
作者信息
Smith Alan D, Truong Mathew, Bristow Rob, Yip Paul, Milosevic Michael F, Joshua Anthony M
机构信息
Princess Margaret Cancer Centre, Toronto, ON, Canada
Department of Biochemistry, University of Toronto, Toronto, ON, Canada.
出版信息
Anticancer Res. 2016 Sep;36(9):4489-92. doi: 10.21873/anticanres.10994.
BACKGROUND/AIM: Carbonic anhydrase IX (CA9) catalyses the interconversion of carbon dioxide to carbonic acid and bicarbonate and is considered a putative biomarker of tumour hypoxia. We set out to evaluate the prognostic significance of CA9 in prostate cancer.
PATIENTS AND METHODS
Plasma samples were assessed from 68 men with high-risk localised prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT), and 20 men with castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy between 2010 and 2012 at the Princess Margaret Cancer Centre, Canada.
RESULTS
Of the 68 patients with high-risk localised prostate cancer, 57 underwent RP and 11 underwent RT. Baseline CA9 was not associated with recurrence or prostate-specific antigen in either group (p=0.98 and 0.20, respectively). CA9 levels before chemotherapy correlated with overall survival (r=-0.37; two-sided p=0.11).
CONCLUSION
Baseline CA9 in men with CRPC may portend a more aggressive prostate cancer phenotype with poorer survival.
背景/目的：碳酸酐酶IX（CA9）催化二氧化碳与碳酸及碳酸氢根之间的相互转化，被认为是肿瘤缺氧的一种假定生物标志物。我们旨在评估CA9在前列腺癌中的预后意义。
患者与方法
对2010年至2012年期间在加拿大玛格丽特公主癌症中心接受治疗的68例接受根治性前列腺切除术（RP）或放疗（RT）的高危局限性前列腺癌男性患者以及20例接受多西他赛化疗的去势抵抗性前列腺癌（CRPC）男性患者的血浆样本进行了评估。
结果
68例高危局限性前列腺癌患者中，57例行RP，11例行RT。两组中基线CA9均与复发或前列腺特异性抗原无关（p值分别为0.98和0.20）。化疗前CA9水平与总生存期相关（r = -0.37；双侧p = 0.11）。
结论
CRPC男性患者的基线CA9可能预示前列腺癌表型更具侵袭性，生存期更差。
Zotero 插件